Investigators sought to determine the long-term safety and efficacy of fremanezumab in patients with chronic migraine and comorbid moderate to severe depression.
All articles by M Tewar, MD
Mark Zimmerman, MD, discusses controversies related to categorizing severity and identifying optimal treatment of depression.
Latest News Your top articles for Wednesday
Haymarket Medical NetworkTop Picks